Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to US Equities

US Equities · Finance research note

ZTS — Zoetis

Research and analysis only
View analysis Browse US Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 36.56%
Profit Margins 28.04%
Return on Equity 67.75%
Return on Assets 15.53%
Free Float 0.42B
Dividend Yield 2.72%
Short Int % Utilisation 3.63%

2.2 Growth

Metric Value
Revenue Growth 2.9%
Free Cash Flow 1.78B
EBITDA 10.16 (Ratio)
Enterprise Value 41.39B
EV/Revenue 4.34
EV/EBITDA 10.16

Revenue growth of 2.9% suggests mature or challenged top-line momentum.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* -47.76%
Risk / Std Dev (Ann.)* 37.14%
1-Year Price Return* -51.20%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $73.79
52-Week Range $71.45 – $160.48
Observation Count 251 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in US$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2025 FY2024
Revenue Reported revenue $9.47B $9.26B
Net income Reported net income $2.67B $2.49B
Total assets Year-end reported balance $15.47B $14.24B
Shareholders’ equity Year-end reported balance $3.33B $4.77B
Net margin Net income ÷ revenue 28.23% 26.86%
Asset turnover Revenue ÷ total assets 0.6121x 0.6501x
Equity multiplier Total assets ÷ shareholders’ equity 4.6434x 2.9847x
ROE Net margin × asset turnover × equity multiplier 80.25% 52.12%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue $9.47B
Prior annual revenue $9.26B
EBIT $3.58B
Tax rate 20.40%
NOPAT = EBIT × (1 − tax rate) $2.85B
Forecast start-growth basis 2.28%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT $2.85B
Add: depreciation & amortisation $487.00M
Less: capital expenditure -$621.00M
Less/(add): working-capital cash-flow movement -$408.00M
Current unlevered FCFF $2.31B

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 2.28% $2.92B $498.10M -$635.16M -$417.30M $2.36B $2.28B
2 2.33% $2.98B $509.73M -$614.92M -$427.04M $2.45B $2.21B
3 2.39% $3.06B $521.91M -$593.72M -$437.25M $2.55B $2.14B
4 2.44% $3.13B $534.67M -$571.45M -$447.94M $2.65B $2.07B
5 2.50% $3.21B $548.04M -$548.04M -$459.14M $2.75B $2.01B

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 0.73
Cost of equity 8.73%
Pre-tax cost of debt 2.78%
WACC 7.22%
WACC validation within standard range

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value $59.75B
Implied terminal EV / EBITDA 13.05x
Terminal value as % of enterprise value 79.74%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF $10.71B
Present value of terminal value $42.17B
Indicated enterprise value $52.88B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value $52.88B
Less: gross interest-bearing debt $9.24B
Add: cash and equivalents $2.31B
Add: affiliate investments $0.00
Less: minority interests $0.00
Indicated common equity value $45.96B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 443,835,000.00
Share-count basis reported diluted weighted-average shares
Current market price $74.09
DCF indicative value per share $103.54
Indicative value vs. market price 39.76%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range pass
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 4/4 evidenced checks
Lynch-inspired balance-and-growth checks 4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:55:38.613420 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation input Value
Regional factor set US
Factor-return currency USD
Issuer-return basis USD adjusted total return
Estimation window 2025-08-19 to 2026-06-30
Aligned daily observations 217
Minimum observation requirement 120
Currency conversion for HK listings not required

Fama–French Three-Factor and Five-Factor Results

Diagnostic FF3 FF5
Annualised alpha -65.74% -58.11%
Adjusted R² 0.10 0.15
Annualised residual volatility 35.47% 34.29%
Factor loading (t-statistic) FF3 FF5
Market excess return (Mkt-RF) 0.73 (3.51) 1.17 (5.02)
Size (SMB) 0.64 (2.28) 0.63 (2.13)
Value (HML) 0.42 (1.73) -0.06 (-0.19)
Profitability (RMW) NM 0.71 (2.87)
Investment (CMA) NM 0.80 (1.87)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

us-equitystockequityztshealth-carepharmaceuticalsnasdaq